Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
基本信息
- 批准号:10947670
- 负责人:
- 金额:$ 60.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-07 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Abstract
Diabetic foot ulcers (DFU) are one of the most common reason for hospitalization of diabetic patients and
frequently it results in amputation of lower limbs. Of the one million people who undergo non-traumatic leg
amputations annually worldwide, 75% are performed on people who have type 2 diabetes (T2DM). The risk of
death at 10 years for a diabetic with DFU is twice as high as the risk for a patient without a DFU. The rate of
amputation in patients with DFU is 38.4%. Infection is a common (>50%) complication of DFU. In those with
DFU, 40% recur within one year after wound closure; 60% within 3 years, and 65% within 5 years. Thus, the
strongest predictor of DFU is a previous foot ulcer. The proposed work rests on a series of pre-clinical and
clinical findings laying the foundation to the hypothesis that biofilm infection of DFU compromises barrier
function of the closed DFU. Such deficient closure paves the way to DFU recurrence. Biofilms are estimated to
account for 60% of chronic wound infections. In the biofilm form, bacteria are in a dormant metabolic state. The
standard clinical techniques like colony forming units (CFU) assay to detect infection may not detect biofilm
infection. Thus, biofilm infection may be viewed as a silent maleficent threat in wound care. The proposed work
is a two-center study – Indiana University and Stanford University – who were competitively funded with a pilot
award by the NIDDK-DIACOMP mechanism to generate preliminary data on DFU closure and recurrence. The
proposed work addresses a novel paradigm in DFU care that has never been tested in a fully powered patient-
based study. Successful execution of the proposed work is likely to have direct impact on the current standards
of wound care including re-defining the most important primary endpoint of wound care, wound closure itself.
For the first time in a DFU patient-based study, mechanisms by which biofilm infection induces molecular
mechanisms that compromise functional integrity of re-epithelialized DFU will be elucidated. In DFU care, the
proposed work may identify that the current endpoint of wound closure (that does not account for any
functional parameter) may be not the right time to stop caring for DFU. That such premature termination of
care may be responsible for the high recurrence of DFU that is currently reported. The notion that continued
care, until functional wound closure is achieved, is necessary to minimize recurrence and amputation would be
of transformative value in the delivery of DFU care. This proposal, wholly based on the study of DFU patients
seeks to conduct a two-centered robust clinical study testing whether wounds with a history of biofilm infection
closes with deficient barrier function (Aim 2). Aim 3 tests whether such deficient wound closure which
manifests as high TEWL is associated with greater wound recurrence. Aim 1 utilizes this patient-based study to
address molecular mechanisms implicated in biofilm-induced loss of skin epithelial barrier integrity.
抽象的
糖尿病足溃疡(DFU)是糖尿病患者住院和
在一百万发生非创伤腿的人中
每年在全球截肢,对患有2型糖尿病(T2DM)的患者进行75%。风险
患有DFU的糖尿病的10年死亡是没有DFU的患者的风险的两倍。速率
DFU患者的截肢为38.4%。感染是DFU的常见并发症(> 50%)。在那些
DFU,在闭风后一年内复发40%; 3年内60%,5年内65%。那,
DFU的最强预测因子是先前的脚溃疡。拟议的工作基于一系列临床前和
临床发现为DFU的生物膜感染损害障碍的假设奠定了基础
封闭DFU的功能。这种不足的闭合为DFU复发铺平了道路。估计生物膜
占慢性伤口感染的60%。在生物膜形式中,细菌处于休眠的代谢状态。这
标准临床技术(例如菌落成型单元(CFU)测定法检测感染可能无法检测到生物膜
感染。这是生物膜感染在伤口护理中的沉默恶毒威胁。拟议的工作
是一项两中心的研究 - 印第安纳大学和斯坦福大学 - 由飞行员竞争性资助
NIDDK-DIACOMP机制授予了有关DFU闭合和复发的初步数据。这
拟议的工作解决了DFU护理中一种新型范式,该范式从未在完全动力的患者中进行过测试 -
基于研究。成功执行拟议的工作可能会对当前标准产生直接影响
包括重新定义伤口护理的最重要的主要终点,伤口护理的伤口护理,伤口闭合本身。
在基于DFU患者的研究中,生物膜感染诱导分子的机制首次
将阐明重新上皮DFU的功能完整性的机制。在DFU护理中
拟议的工作可能会确定当前伤口闭合的终点(这没有考虑到任何
功能参数)可能不是停止关心DFU的合适时机。这样的过早终止
护理可能导致目前报告的DFU的高复发。继续的观念
护理,直到实现功能性伤口闭合,为了最大程度地减少复发性,截肢将是
DFU护理提供的变革价值。该提议完全基于对DFU患者的研究
试图进行两中心的强大临床研究测试是否有生物膜感染史的伤口
以不足的障碍功能关闭(AIM 2)。 AIM 3测试是否会闭合这种缺乏伤口
表现为高TEWL与更大的伤口复发有关。 AIM 1利用此基于患者的研究
解决生物膜诱导的皮肤上皮屏障完整性丧失的分子机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Electrochemical Devices in Cutaneous Wound Healing.
- DOI:10.3390/bioengineering10060711
- 发表时间:2023-06-11
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GEOFFREY C GURTNER其他文献
GEOFFREY C GURTNER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GEOFFREY C GURTNER', 18)}}的其他基金
TARGETING HIF-1α DYSFUNCTION TO TREAT PRESSURE ULCERS IN THE AGED
针对 HIF-1α 功能障碍治疗老年人压疮
- 批准号:
10685482 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
TARGETING HIF-1α DYSFUNCTION TO TREAT PRESSURE ULCERS IN THE AGED
针对 HIF-1α 功能障碍治疗老年人压疮
- 批准号:
10444745 - 财政年份:2022
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10417228 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10256045 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10044343 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Diabetic Foot Ulcer Biofilm Infection and Recurrence
糖尿病足溃疡生物膜感染和复发
- 批准号:
10376509 - 财政年份:2020
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10203948 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10230438 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
Stanford Advanced Wound Care Center Clinical Research Unit
斯坦福高级伤口护理中心临床研究部
- 批准号:
10377776 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
The University of Arizona Wound Care Center Clinical Research Unit
亚利桑那大学伤口护理中心临床研究单位
- 批准号:
10877642 - 财政年份:2018
- 资助金额:
$ 60.71万 - 项目类别:
相似国自然基金
基于激光加工的形状记忆聚合物仿壁虎脚结构制备及其粘附性能调控研究
- 批准号:52305319
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
脚桥核(PPN)胆碱能神经元对帕金森病认知灵活性障碍的调控作用及机制研究
- 批准号:82301595
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
脚间核神经降压素能神经元参与疼痛调控的神经环路与受体机制
- 批准号:82301413
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
DACH1对糖尿病肾病足细胞脂质代谢的调控作用和机制研究
- 批准号:82370719
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
脚桥被盖核谷氨酸能神经元在七氟烷麻醉-觉醒意识转换中的作用及神经环路机制研究
- 批准号:82201413
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Prevention of intracellular infection in diabetic wounds by commensal Staphylococcus epidermidis
共生表皮葡萄球菌预防糖尿病伤口细胞内感染
- 批准号:
10679628 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Home foot-temperature monitoring through smart mat technology to improve access, equity, and outcomes in high-risk patients with diabetes
通过智能垫技术进行家庭足部温度监测,以改善高危糖尿病患者的可及性、公平性和结果
- 批准号:
10539209 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Engineering the open porous nanofibrous microsphere integrated fibrillar hydrogel for the co-delivery of antibacterial and angiogenic agents aimed at the rapid diabetic wound repair
设计开放多孔纳米纤维微球集成纤维水凝胶,用于共同递送抗菌剂和血管生成剂,旨在快速修复糖尿病伤口
- 批准号:
10737115 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Multifunctional Intelligent Hierarchical Fibrous Biomaterials Integrated with Multimodal Biosensing and Feedback-Based Interventions for Healing Infected Chronic Wounds
多功能智能分层纤维生物材料与多模式生物传感和基于反馈的干预措施相结合,用于治愈感染的慢性伤口
- 批准号:
10861531 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别:
Protease Resistant Growth Factor Nanoparticles for Chronic Wound Healing
用于慢性伤口愈合的蛋白酶抗性生长因子纳米颗粒
- 批准号:
10593195 - 财政年份:2023
- 资助金额:
$ 60.71万 - 项目类别: